Global and United States Streptokinase Market Report & Forecast 2022-2028

Streptokinase is indicated for the treatment of AMI, acute massive pulmonary embolism (PE), deep vein thrombosis (DVT), arterial thrombosis, and occluded arteriovenous cannulae.
Market Analysis and Insights: Global and United States Streptokinase Market
This report focuses on global and United States Streptokinase market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Streptokinase market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, High IU accounting for % of the Streptokinase global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Myocardial Infarction (MI) was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Streptokinase market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Streptokinase Scope and Market Size
Streptokinase market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Streptokinase market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Streptokinase market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
High IU
Low IU
Segment by Application
Myocardial Infarction (MI)
Deep Vein Thrombosis
Pulmonary Embolism
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
SAMARTH PHARMA
Biocon
Kee Pharma
Dabur
Biosena
Wanbang Biopharma
Qingdao GD Biotechnology Pharmaceutical
Aristo Pharmaceuticals
Neiss Labs
Ahaan Healthcare Pvt Ltd. (AHPL)
Biofactor
TTK HealthCare
Incepta Pharmaceuticals Limited
Cadila

Frequently Asked Questions